Therapix Biosciences Shares Rise 6% on Partnership with Catalent Pharma For Tourette Syndrome Treatment

Therapix Biosciences (TRPX) shares were higher 6% on Friday after the company said it and Catalent (CTLT) Pharma Solutions will jointly develop and manufacture the investigational drug THX-TS01 for the treatment of the symptoms of Tourette syndrome.

Under the deal, Catalent will develop THX-TS01 in softgel form in support of Therapix’s clinical development program and in accordance with current good manufacturing practice at Catalent’s primary softgel development and manufacturing facility in St. Petersburg, Florida.

“This agreement with Catalent, a world-class drug development, delivery and supply organization, reflects our belief in the promise of THX-TS01 as we look forward to advanced-stage clinical trials and, if successful, commercialization,” said Therapix chairman Ascher Shmulewitz.